These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24189351)

  • 1. Future perspective of cardioplegic protection in cardiac surgery.
    Maruyama Y; Chambers DJ; Ochi M
    J Nippon Med Sch; 2013; 80(5):328-41. PubMed ID: 24189351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion.
    Chambers DJ; Fallouh HB
    Pharmacol Ther; 2010 Jul; 127(1):41-52. PubMed ID: 20398698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in cardioprotection: "polarized" arrest as an alternative to "depolarized" arrest.
    Chambers DJ; Hearse DJ
    Ann Thorac Surg; 1999 Nov; 68(5):1960-6. PubMed ID: 10585111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperpolarized arrest attenuates myocardial stunning following global surgical ischemia: an alternative to traditional hyperkalemic cardioplegia?
    Damiano RJ; Cohen NM
    J Card Surg; 1994 May; 9(3 Suppl):517-25. PubMed ID: 8069046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired cardioplegic delivery and the loss of cardioprotection: a role for preconditioning.
    Galiñanes M; Wilson AN; Hearse DJ
    J Mol Cell Cardiol; 1997 Feb; 29(2):849-54. PubMed ID: 9140842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is blood versus crystalloid cardioplegia relevant? Significantly improved protection may require new cardioplegic concepts!
    Fallouh HB; Chambers DJ
    Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1162-3. PubMed ID: 18784121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial protection in adult cardiac surgery: current options and future challenges.
    Nicolini F; Beghi C; Muscari C; Agostinelli A; Maria Budillon A; Spaggiari I; Gherli T
    Eur J Cardiothorac Surg; 2003 Dec; 24(6):986-93. PubMed ID: 14643818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.
    Yamamoto H; Yamamoto F
    Gen Thorac Cardiovasc Surg; 2013 Sep; 61(9):485-96. PubMed ID: 23877427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of myocyte contractile function after hyperthermic cardioplegic arrest by activation of ATP-sensitive potassium channels.
    Dorman BH; Hebbar L; Hinton RB; Roy RC; Spinale FG
    Circulation; 1997 Oct; 96(7):2376-84. PubMed ID: 9337214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polarization and myocardial protection.
    Chambers DJ
    Curr Opin Cardiol; 1999 Nov; 14(6):495-500. PubMed ID: 10579066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical comparative study between crystalloid and blood-based St Thomas' hospital cardioplegic solution.
    Ibrahim MF; Venn GE; Young CP; Chambers DJ
    Eur J Cardiothorac Surg; 1999 Jan; 15(1):75-83. PubMed ID: 10077377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normokalemic nondepolarizing long-acting blood cardioplegia.
    Malhotra A; Wadhawa V; Ramani J; Garg P; Sharma P; Pandya H; Rodricks D; Tavar R
    Asian Cardiovasc Thorac Ann; 2017; 25(7-8):495-501. PubMed ID: 28975821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C isoform-dependent myocardial protection by ischemic preconditioning and potassium cardioplegia.
    Lu K; Otani H; Yamamura T; Nakao Y; Hattori R; Ninomiya H; Osako M; Imamura H
    J Thorac Cardiovasc Surg; 2001 Jan; 121(1):137-48. PubMed ID: 11135170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent.
    Bessho R; Chambers DJ
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):993-1003. PubMed ID: 11689806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argon preconditioning enhances postischaemic cardiac functional recovery following cardioplegic arrest and global cold ischaemia.
    Kiss A; Shu H; Hamza O; Santer D; Tretter EV; Yao S; Markstaller K; Hallström S; Podesser BK; Klein KU
    Eur J Cardiothorac Surg; 2018 Sep; 54(3):539-546. PubMed ID: 29547976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial function after polarizing versus depolarizing cardiac arrest with blood cardioplegia in a porcine model of cardiopulmonary bypass.
    Aass T; Stangeland L; Moen CA; Salminen PR; Dahle GO; Chambers DJ; Markou T; Eliassen F; Urban M; Haaverstad R; Matre K; Grong K
    Eur J Cardiothorac Surg; 2016 Jul; 50(1):130-9. PubMed ID: 26843432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting for cardioplegia: arresting agents and their safety.
    Fallouh HB; Kentish JC; Chambers DJ
    Curr Opin Pharmacol; 2009 Apr; 9(2):220-6. PubMed ID: 19492439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. A novel form of myocardial protection?
    Cohen NM; Wise RM; Wechsler AS; Damiano RJ
    J Thorac Cardiovasc Surg; 1993 Aug; 106(2):317-28. PubMed ID: 7848379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial protection during minimally invasive cardiac surgery through right mini-thoracotomy.
    De Palo M; Guida P; Mastro F; Nanna D; Quagliara TA; Rociola R; Lionetti G; Paparella D
    Perfusion; 2017 Apr; 32(3):245-252. PubMed ID: 28327076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine instead of supranormal potassium in cardioplegia: it is safe, efficient, and reduces the incidence of postoperative atrial fibrillation. A randomized clinical trial.
    Jakobsen Ø; Næsheim T; Aas KN; Sørlie D; Steensrud T
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):812-8. PubMed ID: 22964356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.